Landiolol Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 300 mg , 600 mg
Reference Brands: Rapibloc (EU)
Category:
Heart Disorder
Landiolol is available in Injection
and strengths such as 300 mg , 600 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Landiolol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Landiolol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Landiolol is an ultra-short-acting, highly β1-selective intravenous beta-adrenergic blocker used for the management of tachycardia and supraventricular arrhythmias such as atrial fibrillation and atrial flutter. It is marketed under brand names including Onoact and Rapiblyk and is administered as landiolol hydrochloride. Landiolol is specifically designed for rapid and precise heart rate control in acute and critical care settings where quick onset and easy titration are essential.
One of the key characteristics of landiolol is its extremely short elimination half-life of approximately 3 to 4 minutes, the shortest among available beta blockers. Its effect on heart rate begins almost immediately after administration, and heart rate typically returns to baseline within about 30 minutes after discontinuation. This allows clinicians to achieve predictable and reversible heart rate control. Due to its high β1-selectivity and pure S-enantiomer structure, landiolol has minimal effects on blood pressure and myocardial contractility compared to other beta blockers, resulting in a lower risk of hypotension.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing